



an Open Access Journal by MDPI

State-of-the-Art Cell Biology and Pathology in Poland

Guest Editors:

Dr. Bartłomiej Tomasiak

Department of Oncology and
Radiotherapy, Faculty of
Medicine, Medical University of
Gdańsk, Gdańsk, Poland

Dr. Marcin Braun

Department of Pathology, Chair
of Oncology, Medical University
of Łódź, Łódź, Poland

Deadline for manuscript
submissions:

closed (30 September 2023)

Message from the Guest Editors

Dear Colleagues,

This Special Issue will provide a comprehensive overview on the state of the art of cell biology and pathology in Poland. We are inviting you to submit manuscripts that will consolidate our understanding in these areas. Full research articles and in-depth reviews will be considered. Topics of interest include, but are not limited to, the following research areas:

- Artificial intelligence and machine learning;
- Cancer biology and pathology stem cells;
- CAR-T cell research;
- Cell physiology: cell growth, metabolism, protein synthesis, division, movement of proteins, active/passive transport, intra- and extracellular signaling, adhesion, DNA repair, etc.;
- Cell signaling;
- Cell techniques: cell and tissue culture, isolation, and fractionation of cells, immunocytochemistry (ICC), in situ hybridization (ISH), transfection, and optogenetics;
- Computational biology and pathology;
- Digital pathology;
- Immune microenvironment and immunotherapy;
- OMICS: transcriptomics, genomics, proteomics, metabolomics, glycomics, lipidomics, interactomics, fluxomics, and biomics;
- Predictive and prognostic biomarkers;
- Stem cell biology.



mdpi.com/si/115786

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)